A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies (CheckMate 370: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 370)
A study for patients with advanced Non small cell lung cancer using study drug Nivolumab
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAQ8181
U.S. Govt. ID: NCT02574078
Contact: Catherine Shu: 212-305-3997 / cas2145@cumc.columbia.edu
Additional Study Information: The purpose of this master study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558) alone or in combination with standard of care therapies.
This study is closed
Catherine Shu, MD
Do You Qualify?
Have you been diagnosed with Non-Small-Cell Lung Cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Catherine Shu